Black Diamond Therapeutic... (BDTX)
| Bid | 1.6 |
| Market Cap | 90.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -69.74M |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | -1.2 |
| Forward PE | -1.97 |
| Analyst | Buy |
| Ask | 1.99 |
| Volume | 1,142,118 |
| Avg. Volume (20D) | 3,345,870 |
| Open | 1.63 |
| Previous Close | 1.67 |
| Day's Range | 1.55 - 1.65 |
| 52-Week Range | 1.54 - 7.66 |
| Beta | 2.52 |
About BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penet...
Analyst Forecast
According to 5 analyst ratings, the average rating for BDTX stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 836.80% from the latest price.
Stock Forecasts
3 months ago · seekingalpha.com
Black Diamond Therapeutics: Speculative Buy With Precision Oncology CatalystsBlack Diamond Therapeutics, Inc.'s BDTX-1535 showed a promising 42% ORR in Phase 2 trials for recurrent EGFR-mutant NSCLC, which addresses treatment-resistant mutations. The MasterKey platform enables...